Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid

Core Viewpoint - The new offer is presented as a superior company proposal compared to Pfizer's bid according to Metsera [1] Company Summary - Metsera claims that their new offer surpasses the existing bid from Pfizer, indicating a competitive landscape in the pharmaceutical industry [1]